{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:19:39Z","timestamp":1789121979572,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-024-00912-y","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:02:16Z","timestamp":1730815336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fabrication of apigenin and adenosine-loaded nanoparticles against doxorubicin-induced myocardial infarction by reducing inflammation and oxidative stress"],"prefix":"10.1186","volume":"24","author":[{"given":"Ruixuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"912_CR1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ijcard.2012.10.046","volume":"168","author":"JA Finegold","year":"2013","unstructured":"Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168:934\u201345.","journal-title":"Int J Cardiol"},{"key":"912_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0140-6736(16)30677-8","volume":"389","author":"GW Reed","year":"2017","unstructured":"Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389:197\u2013210.","journal-title":"Lancet"},{"key":"912_CR3","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1606915","volume":"376","author":"JL Anderson","year":"2017","unstructured":"Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017;376:2053\u201364.","journal-title":"N Engl J Med"},{"key":"912_CR4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJM199205213262107","volume":"326","author":"JE Manson","year":"1992","unstructured":"Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O\u2019Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med. 1992;326:1406\u201316.","journal-title":"N Engl J Med"},{"key":"912_CR5","first-page":"83","volume":"59","author":"S Boateng","year":"2013","unstructured":"Boateng S, Sanborn T. Acute myocardial infarction. Dis DM. 2013;59:83\u201396.","journal-title":"Dis DM"},{"key":"912_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1039\/D2TB00003B","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Gao B, Feng Y. Recent advances in inhibiting atherosclerosis and restenosis: from pathogenic factors, therapeutic molecules to nano-delivery strategies. J Mater Chem B. 2022;10:1685\u2013708.","journal-title":"J Mater Chem B"},{"key":"912_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.05.006","volume":"190","author":"L Wang","year":"2018","unstructured":"Wang L, Ma Q. Clinical benefits and pharmacology of scutellarin: a comprehensive review. Pharmacol Ther. 2018;190:105\u201327.","journal-title":"Pharmacol Ther"},{"key":"912_CR8","doi-asserted-by":"crossref","unstructured":"Pala R, Anju VT, Dyavaiah M, Busi S, Nauli SM. Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases. Int J Nanomed (2020) 3741\u201369.","DOI":"10.2147\/IJN.S250872"},{"key":"912_CR9","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.mtbio.2022.100249","volume":"14","author":"M Karam","year":"2022","unstructured":"Karam M, Fahs D, Maatouk B, Safi B, Jaffa AA, Mhanna R. Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: challenges and future prospects. Mater Today Bio. 2022;14:100249.","journal-title":"Mater Today Bio"},{"key":"912_CR10","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3390\/molecules24152802","volume":"24","author":"P-M Boarescu","year":"2019","unstructured":"Boarescu P-M, Boarescu I, Boc\u0219an IC, Pop RM, Gheban D, Bulboac\u0103 AE, Nicula C, R\u00e2jnoveanu R-M, Bolboac\u0103 SD. Curcumin nanoparticles protect against isoproterenol induced myocardial infarction by alleviating myocardial tissue oxidative stress, electrocardiogram, and biological changes. Molecules. 2019;24:2802.","journal-title":"Molecules"},{"key":"912_CR11","first-page":"6460","volume":"6","author":"S Khan","year":"2020","unstructured":"Khan S, Hasan A, Attar F, Sharifi M, Siddique R, Mraiche F, Falahati M. Gold nanoparticle-based platforms for diagnosis and treatment of myocardial infarction, ACS Biomater. Sci Eng. 2020;6:6460\u201377.","journal-title":"Sci Eng"},{"key":"912_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2013.04.022","volume":"170","author":"M-Y Chang","year":"2013","unstructured":"Chang M-Y, Yang Y-J, Chang C-H, Tang ACL, Liao W-Y, Cheng F-Y, Yeh C-S, Lai JJ, Stayton PS, Hsieh PCH. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release. 2013;170:287\u201394.","journal-title":"J Control Release"},{"key":"912_CR13","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.7150\/thno.26284","volume":"8","author":"J Bejarano","year":"2018","unstructured":"Bejarano J, Navarro-Marquez M, Morales-Zavala F, Morales JO, Garcia-Carvajal I, Araya-Fuentes E, Flores Y, Verdejo HE, Castro PF, Lavandero S, Kogan MJ. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics. 2018;8:4710\u201332. https:\/\/doi.org\/10.7150\/thno.26284.","journal-title":"Theranostics"},{"key":"912_CR14","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.2147\/IJN.S328723","volume":"16","author":"Q Pan","year":"2021","unstructured":"Pan Q., Xu J, Wen C-J, Xiong Y-Y, Gong Z-T, Yang Y-J. Nanoparticles: Promising Tools for the treatment and Prevention of myocardial infarction. Int J Nanomed. 2021;16:6719.","journal-title":"Int J Nanomed"},{"key":"912_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ijpharm.2013.04.015","volume":"454","author":"T Simon-Yarza","year":"2013","unstructured":"Simon-Yarza T, Tamayo E, Benavides C, Lana H, Formiga FR, Grama CN, Ortiz-de-Solorzano C, Kumar MNVR, Prosper F. Blanco-Prieto, functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia. Int J Pharm. 2013;454:784\u201390.","journal-title":"Int J Pharm"},{"key":"912_CR16","doi-asserted-by":"publisher","first-page":"110635","DOI":"10.1016\/j.colsurfb.2019.110635","volume":"185","author":"W Bei","year":"2020","unstructured":"Bei W, Jing L, Chen N. Cardio protective role of wogonin loaded nanoparticle against isoproterenol induced myocardial infarction by moderating oxidative stress and inflammation. Colloids Surf B Biointerfaces. 2020;185:110635.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"912_CR17","doi-asserted-by":"publisher","first-page":"e0132451","DOI":"10.1371\/journal.pone.0132451","volume":"10","author":"K Nagaoka","year":"2015","unstructured":"Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, Tokutome M, Nagahama R, Nakano K, Sunagawa K. A new therapeutic modality for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K\/Akt pathway and anti-inflammation in a rat model. PLoS ONE. 2015;10:e0132451.","journal-title":"PLoS ONE"},{"key":"912_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/biof.1611","volume":"46","author":"L Sun","year":"2020","unstructured":"Sun L, Hu Y, Mishra A, Sreeharsha N, Moktan JB, Kumar P, Wang L. Protective role of poly (lactic-co\u2010glycolic) acid nanoparticle loaded with resveratrol against isoproterenol\u2010induced myocardial infarction. BioFactors. 2020;46:421\u201331.","journal-title":"BioFactors"},{"key":"912_CR19","unstructured":"Xu J, Liu X, Zhang X, Qi K, Zha X. The Protective Effect and Mechanism of Apigenin in Myocardial Ischemia\/Reperfusion Injury by Regulating AMPK\/Nrf2\/HO-1 Pathway, Reperfus. Inj. by Regul. AMPK\/Nrf2\/HO-1 Pathw. (n.d.)."},{"key":"912_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/antiox10101643","volume":"10","author":"W Alam","year":"2021","unstructured":"Alam W, Rocca C, Khan H, Hussain Y, Aschner M, De Bartolo A, Amodio N, Angelone T, Cheang WS. Current status and future perspectives on therapeutic potential of apigenin: focus on metabolic-syndrome-dependent organ dysfunction. Antioxidants. 2021;10:1643.","journal-title":"Antioxidants"},{"key":"912_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11626-020-00434-9","volume":"56","author":"W Li","year":"2020","unstructured":"Li W, Chen L, Xiao Y. Apigenin protects against ischemia-\/hypoxia-induced myocardial injury by mediating pyroptosis and apoptosis. Vitr Cell Dev Biol. 2020;56:307\u201312.","journal-title":"Vitr Cell Dev Biol"},{"key":"912_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/13880209.2019.1701043","volume":"58","author":"W Quan","year":"2020","unstructured":"Quan W, Ma S, Zhu Y, Shao Q, Hou J, Li X. Apigenin-7-O-\u03b2-d-(6 \u2033-p-coumaroyl)-glucopyranoside reduces myocardial ischaemia\/reperfusion injury in an experimental model via regulating the inflammation response. Pharm Biol. 2020;58:80\u20138.","journal-title":"Pharm Biol"},{"key":"912_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/nu15020385","volume":"15","author":"SD Thomas","year":"2023","unstructured":"Thomas SD, Jha NK, Jha SK, Sadek B, Ojha S. Pharmacological and molecular insight on the cardioprotective role of apigenin. Nutrients. 2023;15:385.","journal-title":"Nutrients"},{"key":"912_CR24","doi-asserted-by":"publisher","first-page":"e019899","DOI":"10.1161\/JAHA.120.019899","volume":"10","author":"M Aetesam-ur\u2010Rahman","year":"2021","unstructured":"Aetesam-ur\u2010Rahman M, Brown AJ, Jaworski C, Giblett JP, Zhao TX, Braganza DM, Clarke SC, Agrawal BSK, Bennett MR, West NEJ. Adenosine\u2010Induced Coronary Steal is observed in patients presenting with ST\u2010Segment\u2013elevation myocardial infarction. J Am Heart Assoc. 2021;10:e019899.","journal-title":"J Am Heart Assoc"},{"key":"912_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ehjcvp\/pvac069","volume":"9","author":"R Laborante","year":"2023","unstructured":"Laborante R, Bianchini E, Restivo A, Ciliberti G, Galli M, Vergallo R, Rodolico D, Zito A, Princi G, Leone AM. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Hear Journal-Cardiovascular Pharmacother. 2023;9:173\u201382.","journal-title":"Eur Hear Journal-Cardiovascular Pharmacother"},{"key":"912_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/ph16101473","volume":"16","author":"FS Tallo","year":"2023","unstructured":"Tallo FS, de Santana PO, Pinto SAG, Lima RY, De EA, Ara\u00fajo JGP, Tavares M, Pires-Oliveira LAD, Nicolau JVR, Medeiros MO, Taha. Pharmacological modulation of the Ca2+\/cAMP\/Adenosine Signaling in Cardiac Cells as a New Cardioprotective Strategy to reduce severe arrhythmias in myocardial infarction. Pharmaceuticals. 2023;16:1473.","journal-title":"Pharmaceuticals"},{"key":"912_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14017431.2022.2035807","volume":"56","author":"M Sadeghian","year":"2022","unstructured":"Sadeghian M, Mousavi SH, Aamaraee Z, Shafiee A. Administration of intracoronary adenosine before stenting for the prevention of no-reflow in patients with ST-elevation myocardial infarction. Scand Cardiovasc J. 2022;56:23\u20137.","journal-title":"Scand Cardiovasc J"},{"key":"912_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/biomedicines9020204","volume":"9","author":"MC Procopio","year":"2021","unstructured":"Procopio MC, Lauro R, Nasso C, Carerj S, Squadrito F, Bitto A, Di Bella G, Micari A, Irrera N, Costa F. Role of adenosine and purinergic receptors in myocardial infarction: focus on different signal transduction pathways. Biomedicines. 2021;9:204.","journal-title":"Biomedicines"},{"key":"912_CR29","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C9RA10857B","volume":"10","author":"KY Hern\u00e1ndez-Giottonini","year":"2020","unstructured":"Hern\u00e1ndez-Giottonini KY, Rodr\u00edguez-C\u00f3rdova RJ, Guti\u00e9rrez-Valenzuela CA, Pe\u00f1u\u00f1uri-Miranda O, Zavala-Rivera P, Guerrero-Germ\u00e1n P. Lucero-Acu\u00f1a, PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. RSC Adv. 2020;10:4218\u201331. https:\/\/doi.org\/10.1039\/C9RA10857B.","journal-title":"RSC Adv"},{"key":"912_CR30","doi-asserted-by":"publisher","first-page":"121088","DOI":"10.1016\/j.ijpharm.2021.121088","volume":"608","author":"T Li","year":"2021","unstructured":"Li T, Huang J, Wang M, Wang H. Microfluidic assembly of small-molecule prodrug cocktail nanoparticles with high reproducibility for synergistic combination of cancer therapy. Int J Pharm. 2021;608:121088. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121088.","journal-title":"Int J Pharm"},{"key":"912_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/0002-9378(88)90017-8","volume":"158","author":"DB Cotton","year":"1988","unstructured":"Cotton DB, Lee W, Huhta JC, Dorman KF. Hemodynamic profile of severe pregnancy-induced hypertension. Am J Obstet Gynecol. 1988;158:523\u20139. https:\/\/doi.org\/10.1016\/0002-9378(88)90017-8.","journal-title":"Am J Obstet Gynecol"},{"key":"912_CR32","doi-asserted-by":"publisher","first-page":"165896","DOI":"10.1016\/j.bbadis.2020.165896","volume":"1866","author":"N Romano","year":"2020","unstructured":"Romano N, Ceci M. Are microRNAs responsible for cardiac hypertrophy in fish and mammals? What we can learn in the activation process in a zebrafish ex vivo model. Biochim Biophys Acta - Mol Basis Dis. 2020;1866:165896. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165896.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"912_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.11.071","author":"W Kosol","year":"2019","unstructured":"Kosol W, Kumar S, Marrero-Berr\u00cdos I, Berthiaume F. Medium conditioned by human mesenchymal stromal cells reverses low serum and hypoxia-induced inhibition of wound closure. Biochem Biophys Res Commun. 2019. https:\/\/doi.org\/10.1016\/j.bbrc.2019.11.071.","journal-title":"Biochem Biophys Res Commun"},{"key":"912_CR34","first-page":"335","volume":"38","author":"S Alexiou","year":"2024","unstructured":"Alexiou S, Patoulias D, Theodoropoulos KC, Didagelos M, Nasoufidou A, Samaras A, Ziakas A, Fragakis N, Dardiotis E, Kassimis G. Intracoronary thrombolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials, Cardiovasc. Drugs Ther. 2024;38:335\u201346.","journal-title":"Drugs Ther"},{"key":"912_CR35","first-page":"165","volume":"21","author":"N Kulick","year":"2023","unstructured":"Kulick N, Friede KA, Stouffer GA. Safety and efficacy of intracoronary thrombolytic agents during primary percutaneous coronary intervention for STEMI, Expert Rev. Cardiovasc Ther. 2023;21:165\u201375.","journal-title":"Cardiovasc Ther"},{"key":"912_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-021-01576-2","volume":"23","author":"D Walters","year":"2021","unstructured":"Walters D, Mahmud E. Thrombolytic therapy for St-elevation myocardial infarction presenting to non-percutaneous coronary intervention centers during the COVID-19 crisis. Curr Cardiol Rep. 2021;23:1\u20138.","journal-title":"Curr Cardiol Rep"},{"key":"912_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","volume":"53","author":"NG Frangogiannis","year":"2002","unstructured":"Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31\u201347.","journal-title":"Cardiovasc Res"},{"key":"912_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","volume":"8","author":"D Jen\u010da","year":"2021","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Stehlik J, Stan\u011bk V, Kettner J, Kautzner J, Ad\u00e1mkov\u00e1 V, Wohlfahrt P. Heart failure after myocardial infarction: incidence and predictors. ESC Hear Fail. 2021;8:222\u201337.","journal-title":"ESC Hear Fail"},{"key":"912_CR39","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1021\/acsbiomaterials.6b00509","volume":"3","author":"Z Wang","year":"2017","unstructured":"Wang Z, Long DW, Huang Y, Khor S, Li X, Jian X, Wang Y. Fibroblast growth Factor-1 released from a Heparin Coacervate improves cardiac function in a mouse myocardial infarction model, ACS Biomater. Sci Eng. 2017;3:1988\u201399. https:\/\/doi.org\/10.1021\/acsbiomaterials.6b00509.","journal-title":"Sci Eng"},{"key":"912_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijbiomac.2020.06.097","volume":"162","author":"H Zhang","year":"2020","unstructured":"Zhang H, Chen H, Li J, Bian Y, Song Y, Li Z, He F, Liu S, Tsai Y. Hirudin protects against isoproternol-induced myocardial infraction by alleviating oxidative via an Nrf2 dependent manner. Int J Biol Macromol. 2020;162:425\u201335. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.06.097.","journal-title":"Int J Biol Macromol"},{"key":"912_CR41","doi-asserted-by":"publisher","first-page":"111015","DOI":"10.1016\/j.biopha.2020.111015","volume":"133","author":"J Hou","year":"2021","unstructured":"Hou J, Wang C, Ma D, Chen Y, Jin H, An Y, Jia J, Huang L, Zhao H. The cardioprotective and anxiolytic effects of Chaihujialonggumuli granule on rats with anxiety after acute myocardial infarction is partly mediated by suppression of CXCR4\/NF-\u03baB\/GSDMD pathway. Biomed Pharmacother. 2021;133:111015. https:\/\/doi.org\/10.1016\/j.biopha.2020.111015.","journal-title":"Biomed Pharmacother"},{"key":"912_CR42","doi-asserted-by":"publisher","first-page":"e22543","DOI":"10.1002\/jbt.22543","volume":"34","author":"H Li","year":"2020","unstructured":"Li H, Xia B, Chen W, Zhang Y, Gao X, Chinnathambi A, Alharbi SA, Zhao Y. Nimbolide prevents myocardial damage by regulating cardiac biomarkers, antioxidant level, and apoptosis signaling against doxorubicin-induced cardiotoxicity in rats. J Biochem Mol Toxicol. 2020;34:e22543.","journal-title":"J Biochem Mol Toxicol"},{"key":"912_CR43","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1002\/ctm2.124","volume":"10","author":"C Hu","year":"2020","unstructured":"Hu C, Zhang X, Zhang N, Wei W, Li L, Ma Z, Tang Q. Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clin Transl Med. 2020;10:e124.","journal-title":"Clin Transl Med"},{"key":"912_CR44","doi-asserted-by":"publisher","first-page":"104371","DOI":"10.1016\/j.yexmp.2020.104371","volume":"113","author":"Y He","year":"2020","unstructured":"He Y, Yang Z, Li J, Li E. Dexmedetomidine reduces the inflammation and apoptosis of doxorubicin-induced myocardial cells. Exp Mol Pathol. 2020;113:104371.","journal-title":"Exp Mol Pathol"},{"key":"912_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41467-020-20839-0","volume":"12","author":"I Hwang","year":"2021","unstructured":"Hwang I, Uchida H, Dai Z, Li F, Sanchez T, Locasale JW, Cantley LC, Zheng H, Paik J. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat Commun. 2021;12:640. https:\/\/doi.org\/10.1038\/s41467-020-20839-0.","journal-title":"Nat Commun"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-024-00912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-024-00912-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-024-00912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T02:03:39Z","timestamp":1730858619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-024-00912-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1186\/s12896-024-00912-y","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primarily, adult male SPF rats (weight, 200\u2013250\u00a0g; 10\u201312 weeks old; SLRC Laboratory Animal, Shanghai, China) were used to perform various in vivo functional assessments. All animal procedures and protocols were approved by the animal centre of the Third Xiangya Hospital, Central South University and conformed to the \u201cGuidelines for the Care and Use of Laboratory Animals\u201d published by the U.S. NIH. Ethical approval for this study (Ethical No. 2023\/2\/BP) was obtained from the Ethics Committee of Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}